Olema Pharmaceuticals announced new preclinical data for its lead oral estrogen receptor antagonist, palazestrant, and its KAT6 inhibitor, OP‑3136. The data will be presented in two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.
Palazestrant, a complete estrogen receptor antagonist and selective estrogen receptor degrader, now demonstrates complete blockade of estrogen receptor transcription by recruiting the corepressor protein NCoR1. The confirmation of this mechanism supports the company’s ongoing Phase 3 trials and strengthens the scientific rationale for palazestrant’s clinical development.
Combining palazestrant with OP‑3136 produced synergistic anti‑tumor activity and downregulated metastasis‑related gene signatures in ER‑positive breast cancer models. The findings reinforce Olema’s strategy to address acquired resistance in metastatic disease through dual targeting of estrogen signaling and epigenetic regulation.
The announcement follows Olema’s Q4 2025 financial results, which reported a net loss of $46.1 million and $505.4 million in cash, cash equivalents, and marketable securities. Earnings per share of –$0.50 beat analyst expectations of –$0.52, a beat of $0.02, reflecting disciplined cost management amid increased R&D spending.
Chief Scientific Officer David C. Myles said the data confirm palazestrant’s mechanism of action and highlight the potential of combining KAT6 inhibition with ER antagonism to tackle metastatic disease. He noted that the synergistic activity of OP‑3136 with palazestrant underscores the importance of this combination strategy.
The preclinical results are expected to inform the design of future clinical studies and position Olema for the critical OPERA‑01 readout scheduled for fall 2026, potentially accelerating regulatory and commercial milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.